Currently, lower ANXA2 expression in prostate cancer patients, compared to that in benign prostatic hyperplasia, correlates with an advanced clinical stage, more frequent recurrence, and regional lymph node and distant metastasis and may serve as a useful biomarker [73]. The gene discussed is ANXA2; the disease is prostate carcinoma.